Technology Upgrades Remove Complexity to
Enable Wider Access to Highly Personalized Cancer Care
PALO
ALTO, Calif., July 22,
2024 /PRNewswire/ -- Varian, a
Siemens Healthineers company, has received 510(k) clearance
from the U.S. Food and Drug Administration (FDA) for new
functionality to its Ethos therapy system. Introducing a
streamlined workflow for daily treatment adaptation across more
areas of the body, and providing greater connectivity to patient
data, this latest generation reduces complexity, making it easier
to implement adaptive, personalized radiotherapy.
Ethos 2.0 equips clinical teams with a versatile, comprehensive
solution, optimizing clinical and operational efficiencies with
several new and updated features:
- Enhanced algorithms, driving the Ethos Intelligent
Optimization Engine (IOE), provide a more optimized approach to
treatment planning and dose delivery, allowing for faster
treatment.
- Images acquired using the HyperSight imaging solution, an
option on the Ethos system, are now integrated into the
software to streamline workflows, enabling direct dose calculation
for adapting treatments. This enhancement means clinicians can
create a treatment plan based on that day's anatomy more easily and
more accurately.
- The system significantly expands the number of AI-segmented
anatomical structures that can be automatically contoured,
greatly reducing the need for the time-consuming, manual process of
contouring by hand. This latest version was expanded to include 70+
structures in the head & neck, thorax, abdomen, pelvis, and
bowel regions when using HyperSight images.
- Latest generation optimizes clinical and operational
efficiencies by facilitating seamless data sharing and exchange
with the ARIA CORE oncology management solution for effective
patient management.
"Our latest Ethos system reflects our ongoing commitment to
develop innovative solutions that make real-time, adaptive
radiotherapy treatment easier to accomplish in any setting," said
Arthur Kaindl, Head of Varian. "By
reducing workflow complexity, leveraging advanced, AI-powered
technology, and enabling greater connectivity to patient data
across our ecosystem, we continue to invest in comprehensive tools
to help clinicians integrate precision throughout the patient
journey."
Since its initial launch in 2019, the Ethos system has become an
increasingly valuable radiotherapy tool. Varian data show
that providers who were treating with Ethos chose the adapted
treatment plan 88% of the time as more beneficial for the patient.
Using a single Ethos system, clinicians can choose between online
or offline adaptation – or conventional image-guided radiotherapy
(IGRT) – making this a very versatile system.
VARIAN, HYPERSIGHT, and ETHOS are trademarks of Varian
Medical Systems, Inc., pending or registered U.S. Pat. & Tm.
Off.
About Varian
At Varian, a Siemens Healthineers
company, we envision a world without fear of cancer. For more than
75 years, Varian has developed, built, and delivered innovative
technologies and solutions that help care providers around the
globe treat millions of patients each year. Today, as a Siemens
Healthineers company, we support every step of the cancer care
journey – from screening to survivorship. From advanced imaging and
radiation therapy, to comprehensive software and services, to
interventional radiology, we are harnessing the power of our
perspective while also pursuing clinical research to create a more
efficient, and more personalized care pathway. Because, for cancer
patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com.
Press Contact
Kristin
Corey
Varian Corporate Communications
Kristin.Corey@varian.com
View original
content:https://www.prnewswire.com/news-releases/varian-announces-powerful-functionality-expanding-versatility-and-connectivity-for-its-ethos-adaptive-radiotherapy-system-302202814.html
SOURCE Varian